^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FOLR1 expression

i
Other names: FOLR1, Folate Receptor Alpha, Ovarian Tumor-Associated Antigen MOv18, Adult Folate-Binding Protein, Folate Receptor 1 (Adult), Folate Receptor, Adult, Folate Receptor 1, KB Cells FBP, FR-Alpha, FOLR, FBP, Folate Binding Protein, FRalpha
Entrez ID:
Related biomarkers:
Related tests:
1d
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers. (PubMed, Gynecol Oncol)
Our results highlight a need for standardized protocols for FRα testing to ensure accurate biomarker evaluation across varied clinical settings. The heterogeneity in FRα expression, influenced by tumor histology and anatomical origin, warrant further investigation to optimize therapeutic outcomes.
Journal • Real-world evidence • Real-world
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
VENTANA FOLR1 RxDx Assay
|
Elahere (mirvetuximab soravtansine-gynx)
9d
Deciphering Folate Receptor alphaGene Expression and mRNA Signatures in Ovarian Cancer: Implications for Precision Therapies. (PubMed, Int J Mol Sci)
We identified a gene expression signature correlated to high FRα expression and OC prognosis, which may be used to refine therapeutic strategies targeting FRα in OC. These findings warrant validation in larger cohorts.
Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
18d
Trial completion • Metastases
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
21d
Sonic Hedgehog Is an Early Oligodendrocyte Marker During Remyelination. (PubMed, Cells)
We also report a parallel expression of Shh and MBP in oligodendroglial cells during early post-natal myelination of the mouse brain. Thus, we identify a crucial Shh signal involved in oligodendroglial cell differentiation and remyelination, with potential interest in the design of better-targeted remyelinating therapeutic strategies.
Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • SHH (Sonic Hedgehog Signaling Molecule)
|
FOLR1 expression • PDGFRA expression
22d
The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis. (PubMed, Cancer Med)
FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for second-line and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort.
Clinical • Retrospective data • Review • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
Halaven (eribulin mesylate) • Elahere (mirvetuximab soravtansine-gynx) • luveltamab tazevibulin (STRO-002) • farletuzumab ecteribulin (MORAb-202)
1m
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. (PubMed, Gynecol Oncol)
As demonstrated among 682 participants, the safety profile of MIRV is well tolerated and consists primarily of low-grade gastrointestinal, fatigue, headache, peripheral neuropathy, and resolvable ocular adverse events.
Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
Elahere (mirvetuximab soravtansine-gynx)
2ms
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma. (PubMed, Gynecol Oncol)
Though less than in high-grade disease, a notable portion of low-grade tumors were FOLR1+, suggesting FOLR1 expression in LGSOC could be a viable target for this rare histology, particularly in the recurrent setting.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FOLR1 ( Folate receptor alpha )
|
KRAS mutation • BRAF mutation • NRAS mutation • FOLR1 expression • FOLR1 positive
2ms
Seminal Abstract: Mirvetuximab Soravtansine (MIRV) in Recurrent Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate Receptor-Alpha (FRα) Expression: Results from the PICCOLO Trial (IGCS 2024)
97.5% had prior taxanes, 81% prior poly (ADP-ribose) polymerase inhibitors (PARPi) [74.7% of whom progressed while on PARPi], 64.6% prior bevacizumab, 98.8% had 2+ prior lines of therapy, and BRCA status was 27.8% positive, 72.2% negative. MIRV demonstrated notable efficacy in this heavily pretreated PSOC population, including among those who may have PARPi resistance. MIRV continues to demonstrate a differentiated safety profile consisting primarily of low-grade neurosensory, GI, and resolvable ocular AEs. These data position MIRV to become a novel treatment option for patients in ≥3L PSOC with FRα positive expression.
BRCA Biomarker • PARP Biomarker
|
FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
|
FOLR1 expression
|
VENTANA FOLR1 RxDx Assay
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
2ms
EFFICACY AND SAFETY PROFILE OF MIRVETUXIMAB IN FOLATE RECEPTOR ALPHA-POSITIVE OVARIAN CANCER (IGCS 2024)
Introduction Mirvetuximab soravtansine-gynx (MIRV) is an antibody-drug conjugate that binds to folate receptor alpha and delivers a microtubule inhibitor payload...Median PFS did not significantly differ based on number of prior treatment lines (for 1-3 versus >3 lines, P = 0.3) or prior PARP inhibitor ( P = 0.9) or bevacizumab ( P = 0.4) use...Conclusion/Implications MIRV confers meaningful PFS benefit for a subset of individuals. Biomarkers of response and resistance are urgently needed to optimize patient selection for treatment.
Clinical • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1) • FOLR1 ( Folate receptor alpha )
|
HER-2 amplification • FOLR1 expression • CCNE1 amplification • FOLR1 positive
|
MSK-IMPACT
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
2ms
SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial completion date: Apr 2025 --> Nov 2024
Trial completion date
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
3ms
The evaluation of immunohistochemical research assays in the assessment of folate receptor alpha expression in epithelial ovarian cancer (ECP 2024)
Our data highlight the need for caution in antibody selection when developing immunohistochemical-based assays, as some FRα antibodies failed to cleanly and specifically identify FRα expression. We identified two antibodies appropriate for further investigation; however, as developed, both stain more intensely than the FDAapproved test and may, therefore, over-select patients for treatment with FRα-targeted therapies intended for use with the FDA-approved companion diagnostic. From these data, we advise the use of the FDAapproved assay for patient selection.
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 positive
|
VENTANA FOLR1 RxDx Assay
3ms
Alteration in folate carrier expression via histone deacetylase inhibition in BeWo human placental choriocarcinoma cells. (PubMed, Toxicol In Vitro)
FOLR1 expression was upregulated by VPA, apicidin, and trichostatin A, but downregulated by MS-275 after 24 h treatment. By contrast, HDAC inhibitors exert different regulatory effects on folate carriers. Moreover, HDAC1/2 inhibition may be a potential mechanism involved in altering FOLR1 and SLC46A1 levels.
Journal • Epigenetic controller
|
FOLR1 ( Folate receptor alpha ) • SLC19A1 (Solute Carrier Family 19 Member 1)
|
FOLR1 expression
|
Jingzhuda (entinostat) • trichostatin A (VTR-297)
5ms
Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator's choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression (ESMO 2024)
Here, we report updated nonanalytical results based on a median follow-up of 16.7 months. 453 PROC pts with high FRα expression (VENTANA FOLR1 [FOLR1-2.1] RxDx Assay) with 1-3 prior therapies were randomized 1:1 to MIRV 6 mg/kg, adjusted ideal body weight, Day 1 of a 21-day cycle or ICC: paclitaxel (PAC), pegylated liposomal doxorubicin (PLD), or topotecan (Topo). With a median follow-up of 16.7 months, MIRV demonstrated improved efficacy vs ICC in pts with PROC. The efficacy data, along with the well-characterized safety profile, supports MIRV as the standard of care for pts with FRα positive PROC. Clinical Trial Information: NCT04209855.
P3 data • Clinical
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
VENTANA FOLR1 RxDx Assay
|
paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
5ms
Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial (ESMO 2024)
97.5% had prior taxanes, 81% prior poly (ADP-ribose) polymerase inhibitors (PARPi) [74.7% of whom progressed while on PARPi], 64.6% prior bevacizumab, 98.8% had 2+ prior lines of therapy, and BRCA status was 27.8% positive, 72.2% negative. MIRV demonstrated clinically meaningful antitumor activity and favorable tolerability in patients with FRα-high PSOC. The efficacy and safety data support the use of MIRV in PSOC patients with ≥ 2 prior platinum-containing regimens or platinum allergy. Clinical Trial: NCT05041257.
PARP Biomarker • BRCA Biomarker
|
FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
|
FOLR1 expression
|
VENTANA FOLR1 RxDx Assay
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
5ms
Folate receptor alpha prevalence and association with ovarian cancer patient and disease characteristics (ECP 2024)
Mirvetuximab soravtansine (MIRV), an FRα-targeting antibody-drug conjugate, is active in high-grade serous epithelial ovarian cancer (HGSOC)... FRα was highest in HGSOC and was associated with advanced stage and BRCA status. Sample age, anatomical site, and PFI did not affect FRα expression, suggesting that any sample is suitable for determining FRα status. Variability was observed in cores from the same specimen, which appeared to be driven by tumour heterogeneity versus biological changes.
Clinical • BRCA Biomarker
|
FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
|
FOLR1 expression • BRCA mutation
|
VENTANA FOLR1 RxDx Assay
|
Elahere (mirvetuximab soravtansine-gynx)
7ms
Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer. (PubMed, Medicine (Baltimore))
However, identified gaps, including limited diversity in patient populations, sparse quality of life data, and the need for long-term safety information, indicate areas for future research. Exploration of additional biomarkers predicting mirvetuximab soravtansine responsiveness is essential for personalized treatment.
Review • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
Elahere (mirvetuximab soravtansine-gynx)
7ms
PRO1184-001: PRO1184 for Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=374, Recruiting, ProfoundBio US Co. | N=134 --> 374 | Trial completion date: Sep 2025 --> Apr 2026 | Trial primary completion date: Jan 2025 --> Oct 2025
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
|
HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • rinatabart sesutecan (PRO1184)
7ms
IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer (clinicaltrials.gov)
P2, N=114, Active, not recruiting, ImmunoGen, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Jun 2025
Enrollment closed • Trial primary completion date
|
FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
|
FOLR1 expression
|
carboplatin • Elahere (mirvetuximab soravtansine-gynx)
8ms
Phase classification • Enrollment change
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 positive
|
gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
8ms
Mesenchymal-specific Alms1 knockout in mice recapitulates metabolic features of Alström Syndrome. (PubMed, Mol Metab)
Mesenchymal deletion of Alms1 recapitulates metabolic features of AS, including fatty liver. This confirms a key role for Alms1 in the adipose lineage, where its loss is sufficient to cause systemic metabolic effects and damage to remote organs. Hyperphagia in females may depend on Alms1 deficiency in oligodendrocyte precursor cells rather than neurones. AS should be regarded as a forme fruste of lipodystrophy.
Preclinical • Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
FOLR1 expression • PDGFRA expression
8ms
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. (PubMed, J Gynecol Oncol)
At the current price, MIRV for PROC with high-FRα expression is not the cost-effective strategy in the US. However, its treatment has higher health benefits in bevacizumab-naïve patients, which is likely to be an alternative.
Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
FOLR1 ( Folate receptor alpha ) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
|
FOLR1 expression
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
9ms
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. (PubMed, Gynecol Oncol)
This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable AE profile in participants with recurrent, platinum-sensitive, FRα-expressing ovarian cancer. Thrombocytopenia was the primary cause of dose modifications. These outcomes compare favorably to historical data reported for platinum-based chemotherapy plus bevacizumab regimens in similar patient populations.
P1 data • Journal • Combination therapy
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
Avastin (bevacizumab) • carboplatin • Elahere (mirvetuximab soravtansine-gynx)
10ms
FOLR1 and HER2 Expression in Uterine Serous Carcinoma (USCAP 2024)
Recently, the FDA approved mirvetuximab soravtansine for platinum-resistant ovarian carcinoma with FOLR1 overexpression, typically high-grade serous carcinoma... To our knowledge, this is the largest study to date of FOLR1 expression in USC. Nearly 1 in 5 USC patients are FOLR1+, independent of HER2 status. Further research testing the efficacy of FOLR1-targeted therapy in USC is needed, as approval could potentially double the proportion of patients with available targeted therapies.
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
|
HER-2 amplification • HER-2 expression • FOLR1 expression • FOLR1 overexpression
|
VENTANA FOLR1 RxDx Assay • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
|
Elahere (mirvetuximab soravtansine-gynx)
10ms
Development of an FRα Companion Diagnostic Immunohistochemical Assay for Mirvetuximab Soravtansine. (PubMed, Arch Pathol Lab Med)
Together, these data showed that the assay is highly reliable, consistently producing evaluable results in the clinical setting. The VENTANA FOLR1 Assay is a robust and reproducible assay for detecting FRα expression and identifying a patient population that derived clinically meaningful benefit from MIRV in the SORAYA study.
Journal • Companion diagnostic
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 overexpression
|
Elahere (mirvetuximab soravtansine-gynx)
11ms
P1 data • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
gemcitabine • Elahere (mirvetuximab soravtansine-gynx)
11ms
Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer. (PubMed, Cancers (Basel))
Finally, we performed additional in vitro assays recapitulating immune suppressive mechanisms present in solid tumors and developed a process for the automated manufacturing of our CAR T cell candidate. These findings demonstrate the feasibility of anti-FOLR1 CAR T cells for ovarian cancer and potentially other FOLR1-expressing tumors.
Preclinical • Journal • CAR T-Cell Therapy
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
11ms
Low dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial. (PubMed, Am J Clin Nutr)
Folate transporters are present throughout the terminal ileum and colon; there is little evidence that a low dose folic acid supplementation affects colonic absorption.
Clinical • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
12ms
Trial completion date • Trial primary completion date • Combination therapy
|
FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
|
FOLR1 expression • MUC16 elevation
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
1year
Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer. (PubMed, Postgrad Med J)
FRα-positive CTC detection by noninvasive liquid biopsy is a useful and effective approach for screening of patients with GC.
Journal • Circulating tumor cells • Tumor cell
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 positive
1year
Evaluation of New Folate Receptor-mediated Mitoxantrone Targeting Liposomes In vitro. (PubMed, Curr Pharm Biotechnol)
By modifying folic acid on the surface of liposomes, tumor cells with high expression of folic acid receptors can be effectively targeted, thereby increasing the enrichment of intracellular drugs and improving efficacy. It can also change the delivery pathway, increase the amount of drug entering resistant tumor cells, and overcome resistance.
Preclinical • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
mitoxantrone
1year
EFFICACY AND SAFETY OF MIRVETUXIMAB SORAVTANSINE IN CHINESE PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM IMGN853-301 (SORAYA CHINA) STUDY (IGCS 2023)
All patients received prior bevacizumab; 77% of patients received a prior PARP inhibitor. As of the data cutoff of 25-April-2023, median follow-up was 4.5 months. In all of 35 evaluable patients by investigator per RECIST 1.1, confirmed and unconfirmed ORR was 31.4% (95% CI: 16.85%, 49.29%), and 3-month PFS rate was estimated as 73.5%(95% CI: 55.30%, 85.25%). The most common (≥20%) treatment-related adverse events (all grade and grade 3-4) were Keratopathy (57.1% and 14.3%) , Aspartate aminotransferase increased (45.7% and 0%), White blood cell count decreased (37.1% and 2.9%), Alanine aminotransferase increased (37.1% and 0%), Vision blurred (37.1% and 17.1%), Platelet count decreased (37.1% and 5.7%), Neutrophil count decreased (37.1% and 5.7%), and Xerophthalmia (20.0% and 14.3%).
Clinical • PARP Biomarker
|
FOLR1 ( Folate receptor alpha ) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
|
FOLR1 expression
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
1year
CHARACTERIZATION OF FOLATE RECEPTOR ALPHA EXPRESSION IN NON-HIGH-GRADE SEROUS GYNECOLOGIC TUMORS (IGCS 2023)
Introduction: Mirvetuximab soravtansine (MIRV) is an anti-folate receptor alpha (FOLR1)-drug conjugate... 41 cervical squamous cell carcinoma (SCC), 35 endocervical adenocarcinoma, 21 uterine serous carcinoma, 14 uterine carcinosarcoma, and 48 ovarian clear cell carcinoma (OCCC) cases were represented in the TMAs and stained with FOLR1 (see Figure 1). 0% of cervical SCC, 0% of endocervical adenocarcinoma, 14% of uterine serous carcinoma, 0% of uterine carcinosarcoma, and 0% of OCCC cases met current FOLR1 positivity criteria (PS2 ≥ 75%) (see Table 1). Figure 1: Examples of H&E and FOLR1 staining in endocervical adenocarcinoma (A-B), uterine serous carcinoma (C-D), and ovarian clear cell carcinoma (E- F) Table 1: FOLR1 PS2 scores of different tumor types Conclusion/Implications: Variable FOLR1 expression was seen in different gynecologic tumor types.
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 positive
|
VENTANA FOLR1 RxDx Assay
|
Elahere (mirvetuximab soravtansine-gynx)
1year
P1/2 data • Clinical • Metastases
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
VENTANA FOLR1 RxDx Assay
|
rinatabart sesutecan (PRO1184)
1year
Astrocyte lipocalin-2 modestly effects disease severity in a mouse model of multiple sclerosis while reducing mature oligodendrocyte protein and mRNA expression. (PubMed, Neurosci Lett)
Immunostaining and qPCR of spinal cord samples showed decreased oligodendrocyte proteolipid protein and transcription factor Olig2 expression, but no changes in PDGFRα expression. These results suggest astrocyte LCN2 contributes to early events in EAE and reduces damage to mature oligodendrocytes at later times.
Preclinical • Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • LCN2 (Lipocalin-2) • GFAP (Glial Fibrillary Acidic Protein) • OLIG2 (Oligodendrocyte Transcription Factor 2)
|
FOLR1 expression • PDGFRA expression
1year
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. (PubMed, Gynecol Oncol)
FRα expression was observed in all the UCS and OCS specimens, including HER2-negative UCS patients. This widespread FRα expression suggests that FRα-targeted therapies may hold promise for the treatment for gynecologic carcinosarcoma. However, in uterine carcinosarcoma, no significant relationship was observed between FRα expression and clinicopathological features or prognosis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
|
HER-2 negative • HER-2 expression • FOLR1 expression
over1year
Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics. (PubMed, Cell Signal)
Chromatin immunoprecipitation, overexpression of mutant YAP1, and treatment with YAP1-TEAD (TEA domain transcription factors) complex inhibitor verteporfin demonstrated regulation of FOLR1 expression by YAP1 and its partner transcription factor TEAD2. By identifying the influence of YAP1-FOLR1 link in DNA damage, our findings suggest that simultaneous depletion of both could amplify the potency of DNA damaging agents, while concomitantly reducing the release of inflammatory mediators and potentially affecting immune modulation. This study also highlights the novel role of FOLR1 as a probable prognostic marker in gliomas, predicting responsiveness to temozolomide and other DNA damaging agents.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FOLR1 ( Folate receptor alpha ) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • YAP1 (Yes associated protein 1)
|
IDH1 mutation • FOLR1 expression • IDH wild-type
|
temozolomide • Visudyne (verteporfin)
over1year
First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors (ESMO 2023)
The Q2W regimen had a better hematological safety profile with no related discontinuations. Conclusions Safety and efficacy of ELU001 demonstrated expected, manageable safety profile based on the payload, exatecan, with promising activity in heavily pretreated patients across several cancer indications with low, moderate or high FRα expression.
Clinical • P1 data
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
ELU001
over1year
Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes (ESMO 2023)
Intratumoral imaging analysis using tumors on day 21st showed an association between the antitumor effect and intratumoral accumulation of eribulin. Conclusions These results suggest that FZEC may be a promising treatment for FRα-expressing EC of all four molecular subtypes.
Clinical • MSi-H Biomarker
|
MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • FOLR1 ( Folate receptor alpha )
|
MSI-H/dMMR • POLE mutation • FOLR1 expression
|
Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
over1year
Mirvetuximab Soravtansine Demonstrates Longer Overall Survival And Progression-Free Survival By Prior Lines Of Therapy Vs Chemotherapy In Platinum-Resistant Ovarian Cancer And High Folate Receptor Alpha Expression In The MIRASOL Trial (ESGO 2023)
Methodology 453 PROC pts with high FRα expression (Roche FOLR1 Assay), 1-3 PLOT were randomized 1:1 to MIRV or IC: paclitaxel, pegylated liposomal doxorubicin, or topotecan. MIRV is the first treatment to demonstrate both an OS and a PFS benefit in a phase III trial in PROC. These efficacy data, along with the well-characterized safety profile, position MIRV as a new standard of care for pts with FRα positive PROC.
Clinical
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
over1year
Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. (PubMed, Expert Rev Anticancer Ther)
The National Comprehensive Cancer Network (NCCN) ovarian cancer 2023 guidelines adopted mirvetuximab as 2A, and mirvetuximab combined with bevacizumab as 2B, recommendations. Mirvetuximab represents the first biomarker-directed therapy with an indication specifically for the treatment of PROC. The efficacy and favorable safety profile support further development of mirvetuximab and mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer.
Review • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
over1year
Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women. (PubMed, Life Sci)
A number of methods have been developed to target FOLR1 in cancer therapy, including the development of FOLR1-targeted imaging agents for cancer diagnosis and the use of folate conjugates to deliver cytotoxic agents to cancer cells that overexpress FOLR1. Therefore, we focus on the most recent developments in employing FOLR1 for cancer diagnosis and treatment in this review, particularly with regard to cancers that affect women.
Review • Journal
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression • FOLR1 overexpression